Berenberg Downgrades Bristol-Myers Squibb Co. (BMY) to Hold

August 11, 2016 6:57 AM EDT
Get Alerts BMY Hot Sheet
Price: $49.23 --0%

Rating Summary:
    9 Buy, 13 Hold, 5 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 3 | New: 10
Trade BMY Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Berenberg downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Hold with a price target of $70.00.

Analyst Laura Sutcliffe commented, "One of the key risks to the short-term Buy case for Bristol has crystallised. Following the failure of CheckMate 026 – which evaluated IO drug Opdivo as monotherapy in first-line NSCLC in PD-L1 positive patients – we downgrade our recommendation for Bristol from Buy to Hold. While a lack of success in this particular trial has no impact on about half of Bristol’s IO opportunity, it affects the NSCLC space as a whole, and places Bristol on the back foot in a market where it has, up until now, dominated."

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $60.58 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Add Your Comment